Omnicell (OMCL) Notes Payables (2021 - 2025)

Omnicell (OMCL) posted quarterly Notes Payables of $174.8 million for Q2 2025, little changed quarter-over-quarter from $174.6 million in Q1 2025.

Omnicell (OMCL) Notes Payables (2021 - 2025) Analysis & Trends

Omnicell (OMCL) has reported Notes Payables for 4 consecutive years, with $174.8 million the latest figure, recorded in Q2 2025.

In Q2 2025, Notes Payables changed N/A year-over-year to $174.8 million; the TTM figure through Jun 2025 stood at $174.8 million (changed N/A YoY), while the FY2024 annual figure was $174.3 million, changed N/A from the prior year.
Notes Payables was little changed at $174.8 million in Q2 2025 per OMCL's latest filing, from $174.6 million in the prior quarter.
Across five years, Notes Payables topped out at $572.0 million in Q3 2024 and bottomed at $174.3 million in Q4 2024.
Historically, Notes Payables has averaged $358.0 million across 4 years, with a median of $331.5 million in 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Veeva Systems	39.72 Bn	32.40 Bn	662.02 Mn
2	BrightSpring Health Services	12.19 Bn	11.64 Bn	492.75 Mn
3	Healthequity	8.79 Bn	8.52 Bn	256.31 Mn
4	10x Genomics	7.31 Bn	6.76 Bn	112.50 Mn
5	Hinge Health	7.10 Bn	6.71 Bn	183.95 Mn
6	MiniMed	5.66 Bn	5.36 Bn	480.00 Mn
7	Waystar Holding	4.76 Bn	4.56 Bn	221.99 Mn
8	Doximity	4.46 Bn	3.77 Bn	132.93 Mn
9	Heartflow	3.66 Bn	3.28 Bn	53.19 Mn
10	Omnicell	1.70 Bn	1.41 Bn	152.94 Mn

Download Data